BAY 86-9766 offers survival benefit in mouse model of pancreatic cancer. Treatment yields remarkable tumor regression rapidly. Therapy effective in mice with advanced tumors. LAKE TAHOE, Nev. — A novel chemotherapeutic agent, the highly selective MEK1/2 inhibitor BAY 86-9766, may be a promising...
Posted to
News
by
AACR News
on
Wed, Jun 20 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, chemotherapy, pancreatic cancer, preclinical studies, Pancreatic Cancer: Progress and Challenges, Dr. Nicole Teichmann
Cancer stem cells sensitive to metabolic reprogramming with metformin. Metformin effectively combined with standard pancreatic treatments. Approach ready for clinical trials. LAKE TAHOE, Nev. — Results of some preclinical trials have shown that low doses of the antidiabetic drug metformin may effectively...
Posted to
News
by
AACR News
on
Tue, Jun 19 2012
Filed under:
Filed under: Press Releases, diabetes, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, stem cells, pancreatic cancer, preclinical studies, Metformin, Pancreatic Cancer: Progress and Challenges, Dr. Christopher Heeschen
High levels of hypoxia in xenografted pancreatic tumors predict aggressive growth and enhanced metastatic potential. Treatment efficacy of the hypoxia-targeting prodrug TH-302 depended on level of hypoxia and tumor growth rate. Results provide additional rationale for ongoing clinical trials with TH...
Posted to
News
by
AACR News
on
Tue, Jun 19 2012
Filed under:
Filed under: Press Releases, radiation, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, pancreatic cancer, tumor growth, preclinical studies, hypoxia, Pancreatic Cancer: Progress and Challenges, TH-302, Dr. Ines Lohse
Recently discovered BRAF inhibitors may prevent drug-induced skin lesion side effects and lead to greater treatment durability. Mechanism of drug-induced skin lesions is explored in preclinical model. SAN FRANCISCO — Findings from preclinical studies in a skin cancer model showed that next-generation...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, skin cancer, EGFR, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, preclinical studies, Dr. Gideon Bollag, oncogenes, BRAF
VEGF and Ang2 are critical factors required for tumor angiogenesis. Combined blockade of VEGF and Ang2 with investigational agents enhances antitumor activity in preclinical studies. Combination of REGN910 with aflibercept warrants further clinical investigation. SAN FRANCISCO — Combining the investigational...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, angiogenesis, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, antiangiogenesis, antitumor, Ang2, Dr. Alshad S. Lalani, REGN910, aflibercept, combination therapy, VEGF, preclinical studies